Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers

Completed · Phase 1

Conditions studied: Healthy

In brief

The current study is designed to estimate the effect of rifampin (600 mg orally every 24 hours for 7 days) on pharmacokinetics of single 30 mg dose (CP-690,550) in normal healthy volunteers

Key facts

Study ID

NCT01204112

Run by

Pfizer

People needed

12

Starts

2010-09-01

Expected to finish

2010-10-01

Last updated by the study team

2010-10-22

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy male and/or female subjects (of non-childbearing potential)

You may not qualify if…

• Clinically significant disease or condition
• Recent serious infection

Where it is running

• Pfizer Investigational Site — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.